论文部分内容阅读
目的观察鲨鱼软骨素对晚期非小细胞肺癌的抗肿瘤作用。方法收集确诊为Ⅲb期和Ⅳ期非小细胞肺癌的患者56例,随机分为两组,均应用吉西他滨联合顺铂或单药多西他赛化疗,其中治疗组加服鲨鱼软骨素胶囊,观察其疗效、毒副作用及生存期,进行统计学分析。结果治疗组临床受益率(71.4%),对照组39.3%,差异有显著性(Uc=2.56,P<0.05)。治疗组和对照组毒副反应发生率分别为64.2%和71.4%,差异无显著性(χ2=0.33,P>0.05)。治疗组3年生存率为53.6%,对照组为21.4%,差异有显著性(χ2=6.17,P<0.05)。结论鲨鱼软骨素联合化疗治疗晚期非小细胞肺癌能明显提高有效率,降低毒副反应,提高患者生存率。
Objective To observe the antitumor effect of shark chondroitin on advanced non-small cell lung cancer. Methods Fifty-six patients with stage Ⅲb and Ⅳ non-small cell lung cancer were enrolled in the study. They were randomly divided into two groups. All of them were treated with gemcitabine combined with cisplatin or single-agent docetaxel. Shark chondroitin capsules were added to the treatment group. Its efficacy, toxic side effects and survival, for statistical analysis. Results The clinical benefit rate (71.4%) in the treatment group and 39.3% in the control group were significantly different (Uc = 2.56, P <0.05). The incidence of side effects in treatment group and control group were 64.2% and 71.4% respectively, with no significant difference (χ2 = 0.33, P> 0.05). The 3-year survival rate was 53.6% in the treatment group and 21.4% in the control group, with significant difference (χ2 = 6.17, P <0.05). Conclusion Shark chondroitin combined with chemotherapy for advanced non-small cell lung cancer can significantly improve the efficiency, reduce side effects and improve patient survival.